ADMA Biologics, Inc. (NASDAQ:ADMA) Position Raised by Veracity Capital LLC

Veracity Capital LLC raised its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 117.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,415 shares of the biotechnology company’s stock after purchasing an additional 25,030 shares during the quarter. Veracity Capital LLC’s holdings in ADMA Biologics were worth $796,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Hollencrest Capital Management bought a new position in ADMA Biologics during the third quarter valued at about $30,000. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $31,000. GAMMA Investing LLC raised its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. National Bank of Canada FI acquired a new stake in ADMA Biologics during the third quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics during the third quarter valued at approximately $62,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 0.7 %

ADMA Biologics stock opened at $16.58 on Friday. ADMA Biologics, Inc. has a 52 week low of $5.02 and a 52 week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of 59.21 and a beta of 0.76. The company has a 50 day moving average price of $18.69 and a 200 day moving average price of $17.40.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter last year, the firm posted $0.01 earnings per share. Research analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.